Wellmark Blue Cross and Blue Shield announced it will continue to waive the cost share for members undergoing inpatient treatment related to a COVID-19 diagnosis through March 31, 2021. The extension provides Wellmark members with extended relief from copays, coinsurance and deductibles for inpatient treatment of COVID-19 from an in-network health care provider. The waiver, originally put into place on April 1, was scheduled to expire at the end of 2020. “This extension affirms the commitment we made to our members early on — no one should worry or delay getting tested or treated for this virus because they are concerned about how they will pay for it,” said Cory Harris, Wellmark president and CEO-elect. Wellmark will also continue to cover appropriate testing and related services — with no cost share — to establish the diagnosis of COVID-19. As the vaccination doses begin to be administered, Wellmark’s fully insured health plans will pay for the administration of the COVID-19 vaccine at no member cost-share, consistent with the CARES Act. Once the federal government stops paying for COVID-19 vaccination doses, Wellmark’s fully-insured health plans will also cover COVID-19 vaccination doses at no member cost share under the Affordable Care Act as a preventive service.